<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325739</url>
  </required_header>
  <id_info>
    <org_study_id>CFGF401X2101</org_study_id>
    <nct_id>NCT02325739</nct_id>
  </id_info>
  <brief_title>FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression</brief_title>
  <official_title>A Phase I/II, Multicenter, Open-label Study of Oral FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401
      as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and
      as single agent in patients with other solid malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estimate the maximum tolerated dose and/or recommended phase II dose by detecting the Dose
      Limiting Toxicity and efficacy of FGF401 as single agent and in combination with PDR001 in
      patients with hepatocellular carcinoma and as single agent in patients with other solid
      malignancies based on RECIST 1.1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2014</start_date>
  <completion_date type="Anticipated">May 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of Dose-limiting Toxicity (DLT)</measure>
    <time_frame>Cycle 1 (21 days) for FGF401 single agent; Cycle 1 and Cycle 2 (42 days) for FGF401 in combination with PDR001</time_frame>
    <description>For Phase l parts only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Up to 6 months.</time_frame>
    <description>FGF401 single agent-Phase II part - Group 1 and Group 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Up to 6 months.</time_frame>
    <description>FGF401 single agent-Phase II part - Group 3 and FGF401 in combination with PDR001-Phase II</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events (AEs)/serious adverse events (SAEs)</measure>
    <time_frame>Continuously throughout the study until 30 days after FGF401 discontinuation or 150 days after PDR001 discontinuation</time_frame>
    <description>Incidence and severity of AEs, SAEs, changes in laboratory values, vital signs and ECGs, dose interruptions and reductions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)- phase I and phase II parts</measure>
    <time_frame>From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Up to 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)- phase I parts and FGF401 single agent phase II Group 1 and Group 2 and FGF401 in combination with PDR001 Phase II part</measure>
    <time_frame>From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Up to 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)- phase I and phase II parts</measure>
    <time_frame>From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Up to 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)- phase I parts and FGF401 in combination with PDR001 Phase II part</measure>
    <time_frame>From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Up to 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)- phase I and phase II parts</measure>
    <time_frame>Start of study drug to Survival Endpoint, Average 9 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)- FGF401 single agent phase II Group 3 and FGF401 in combination with PDR001 Phase II part</measure>
    <time_frame>From baseline, then every second cycle (i.e. approximately every 6 weeks), until disease progression or discontinuation from study. Up to 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of FGF401</measure>
    <time_frame>During phase I parts: Cycle 1 Day 1, 2, 8, 9, 15, Cycle 2 Day 1, 2, Cycle 3 Day 1 and Cycle 4 Day 1; during phase II parts: Cycle 1 Day 1, 2, 8, 15, Cycle 2 Day 1, 2 and Day 1 of Cycle 3 to Cycle 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of PDR001</measure>
    <time_frame>For FGF401 in combination with PDR001 phase I part: C1 D1,8,15, C2 D1, C3 D1,15, D1 of Cycle 4 to 6, apprx. 10mo after C1D1, 150-day safety FU; and phase II part: Day 1 of Cycle 1 to 6, apprx. 10mo after C1D1 and 150-day safety FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and/or concentration of anti-PDR001 antibodies</measure>
    <time_frame>For FGF401 in combination with PDR001 phase I and phase II parts: Day 1 of Cycle 1 to 6, apprx. 10mo after C1D1 and 150-day safety FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of PDR001</measure>
    <time_frame>For FGF401 in combination with PDR001 phase I part: C1 D1,8,15, C2 D1, C3 D1,15, D1 of Cycle 4 to 6, apprx. 10mo after C1D1, 150-day safety FU; and phase II part: Day 1 of Cycle 1 to 6, apprx. 10mo after C1D1 and 150-day safety FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of PDR001</measure>
    <time_frame>For FGF401 in combination with PDR001 phase I part: C1 D1,8,15, C2 D1, C3 D1,15, D1 of Cycle 4 to 6, apprx. 10mo after C1D1, 150-day safety FU; and phase II part: Day 1 of Cycle 1 to 6, apprx. 10mo after C1D1 and 150-day safety FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of PDR001</measure>
    <time_frame>For FGF401 in combination with PDR001 phase I part: C1 D1,8,15, C2 D1, C3 D1,15, D1 of Cycle 4 to 6, apprx. 10mo after C1D1, 150-day safety FU; and phase II part: Day 1 of Cycle 1 to 6, apprx. 10mo after C1D1 and 150-day safety FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of PDR001</measure>
    <time_frame>For FGF401 in combination with PDR001 phase I part: C1 D1,8,15, C2 D1, C3 D1,15, D1 of Cycle 4 to 6, apprx. 10mo after C1D1, 150-day safety FU; and phase II part: Day 1 of Cycle 1 to 6, apprx. 10mo after C1D1 and 150-day safety FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau of PDR001</measure>
    <time_frame>For FGF401 in combination with PDR001 phase I part: C1 D1,8,15, C2 D1, C3 D1,15, D1 of Cycle 4 to 6, apprx. 10mo after C1D1, 150-day safety FU; and phase II part: Day 1 of Cycle 1 to 6, apprx. 10mo after C1D1 and 150-day safety FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of PDR001</measure>
    <time_frame>For FGF401 in combination with PDR001 phase I part: C1 D1,8,15, C2 D1, C3 D1,15, D1 of Cycle 4 to 6, apprx. 10mo after C1D1, 150-day safety FU; and phase II part: Day 1 of Cycle 1 to 6, apprx. 10mo after C1D1 and 150-day safety FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of FGF401</measure>
    <time_frame>During phase I parts: Cycle 1 Day 1, 2, 8, 9, 15, Cycle 2 Day 1, 2, Cycle 3 Day 1 and Cycle 4 Day 1; during phase II parts: Cycle 1 Day 1, 2, 8, 15, Cycle 2 Day 1, 2 and Day 1 of Cycle 3 to Cycle 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of FGF401</measure>
    <time_frame>During phase I parts: Cycle 1 Day 1, 2, 8, 9, 15, Cycle 2 Day 1, 2, Cycle 3 Day 1 and Cycle 4 Day 1; during phase II parts: Cycle 1 Day 1, 2, 8, 15, Cycle 2 Day 1, 2 and Day 1 of Cycle 3 to Cycle 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of FGF401</measure>
    <time_frame>During phase I parts: Cycle 1 Day 1, 2, 8, 9, 15, Cycle 2 Day 1, 2, Cycle 3 Day 1 and Cycle 4 Day 1; during phase II parts: Cycle 1 Day 1, 2, 8, 15, Cycle 2 Day 1, 2 and Day 1 of Cycle 3 to Cycle 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of FGF401</measure>
    <time_frame>During phase I parts: Cycle 1 Day 1, 2, 8, 9, 15, Cycle 2 Day 1, 2, Cycle 3 Day 1 and Cycle 4 Day 1; during phase II parts: Cycle 1 Day 1, 2, 8, 15, Cycle 2 Day 1, 2 and Day 1 of Cycle 3 to Cycle 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau of FGF401</measure>
    <time_frame>During phase I parts: Cycle 1 Day 1, 2, 8, 9, 15, Cycle 2 Day 1, 2, Cycle 3 Day 1 and Cycle 4 Day 1; during phase II parts: Cycle 1 Day 1, 2, 8, 15, Cycle 2 Day 1, 2 and Day 1 of Cycle 3 to Cycle 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of FGF401</measure>
    <time_frame>During phase I parts: Cycle 1 Day 1, 2, 8, 9, 15, Cycle 2 Day 1, 2, Cycle 3 Day 1 and Cycle 4 Day 1; during phase II parts: Cycle 1 Day 1, 2, 8, 15, Cycle 2 Day 1, 2 and Day 1 of Cycle 3 to Cycle 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>HCC</condition>
  <arm_group>
    <arm_group_label>FGF401 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 168 patients enrolled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FGF401 in combination with PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 70 patients enrolled</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FGF401</intervention_name>
    <description>FGF401 is a FGFR4 inhibitor.</description>
    <arm_group_label>FGF401 single agent</arm_group_label>
    <arm_group_label>FGF401 in combination with PDR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2</description>
    <arm_group_label>FGF401 in combination with PDR001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ECOG Performance Status ≤ 1

          2. Presence of at least one measurable lesion according to RECIST v1.1. c-i) FGF401
             single agent-Phase I and Phase II, Group 3: Patients with HCC or advanced solid
             tumors, who have progressed despite standard therapy or are intolerant of standard
             therapy, or for whom no standard therapy exists. c-ii) FGF401 single agent-Phase II,
             Groups 1 and 2: HCC patients previously treated with sorafenib for advanced HCC with
             documented disease progression during or after discontinuation of sorafenib treatment,
             or intolerance to sorafenib treatment c-iii) FGF401 in combination with
             PDR001:Advanced HCC patients who have received up to 2 previous lines of systemic
             treatment and one treatment must have included sorafenib with documented disease
             progression during or after discontinuation of sorafenib treatment, or intolerance to
             sorafenib treatment

        Exclusion Criteria:

          1. Previous treatment with a selective FGF19-FGFR4 targeted therapy and/or pan-FGFR
             inhibitor.

          2. Symptomatic CNS metastases which are neurologically unstable or requiring increasing
             doses of steroids to control their CNS disease.

          3. Patient having out of range laboratory values defined as:

               -  Hematology Hemoglobin ≤ 9 g/dL (SI Units: 90 g/L) Platelet count &lt; 75000/mm3
                  Absolute neutrophil count (ANC) &lt; 1500/mm3

               -  Chemistry Total bilirubin ≥ 2 mg/dL AST and/or ALT &gt; 3 x ULN Serum creatinine &gt;
                  1.5 x ULN and/or creatinine clearance ≤ 45 mL/min

               -  Coagulation: PT &gt; 4 seconds more than ULN or INR &gt; 1.7

          4. Pregnant or nursing (lactating) women.

        Other protocol-defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra R. Sandoval</last_name>
      <phone>310-582-4069</phone>
      <email>SSandoval@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Richard S. Finn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy A Gisondi</last_name>
      <phone>617-724-9533</phone>
      <email>agisondi@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Han Kinahan</last_name>
      <phone>+1 713 792 2921</phone>
      <email>hkinahan@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Shubham Pant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes Cedex</city>
        <state>Ille Et Vilaine</state>
        <zip>35062</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pessac cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <state>Taiwan ROC</state>
        <zip>70421</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>December 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2014</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FGF401, PDR001, PD-1, FGFR4, FGF19, HCC</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

